key: cord-0899973-2t0zwml5
authors: Chuang, Hong-Meng; Ho, Li-Ing; Harn, Horng-Jyh; Liu, Ching-Ann
title: Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis
date: 2021-04-12
journal: Cell Transplant
DOI: 10.1177/0963689721996217
sha: ced8b48091ecafba5308edfec2abec9f0fc3e1bf
doc_id: 899973
cord_uid: 2t0zwml5

COVID-19 has spread worldwide, including the United States, United Kingdom, and Italy, along with its site of origin in China, since 2020. The virus was first found in the Wuhan seafood market at the end of 2019, with a controversial source. The clinical symptoms of COVID-19 include fever, cough, and respiratory tract inflammation, with some severe patients developing an acute and chronic lung injury, such as acute respiratory distress syndrome (ARDS) and pulmonary fibrosis (PF). It has already claimed approximately 300 thousand human lives and the number is still on the rise; the only way to prevent the infection is to be safe till vaccines and reliable treatments develop. In previous studies, the use of mesenchymal stem cells (MSCs) in clinical trials had been proven to be effective in immune modulation and tissue repair promotion; however, their efficacy in treating COVID-19 remains underestimated. Here, we report the findings from past experiences of SARS and MSCs, and how SARS could also induce PF. Such studies may help to understand the rationale for the recent cell-based therapies for COVID-19.

The SARS-CoV-2 virus, originating from bat coronavirus, broke out in Wuhan, a city with a population of 11 million that spent months under strict lockdown since the outbreak. This virus belongs to the family Coronaviridae and genus Betacoronavirus, same as the human SARS-CoV, MERS-CoV, and human CoV-HKU, which were found to infect humans. A devastating effect in SARS-CoV-2-infected patients is severe acute respiratory syndrome, the symptoms including fever, cough, fatigue, shortness of breath, and loss of smell. With progress of the disease, acute lung injury might lead to ARDS or PF. While some research groups have reported the ARDS to not be like the typical syndrome 1 , histopathological findings have shown the occurrence of interstitial fibrosis in a critical patient with COVID-19 2 . Another feature in patients with COVID-19 is cytokine storm syndrome 3 , making a significant difference between the dead and discharged patients 4 . These features are common with those seen in SARS in 2003 and could possibly be due to the similarities between the viruses 5 .

Severe acute respiratory syndrome (SARS) is an infectious disease that causes severe respiratory illness and even death. Although PF may be seen in other respiratory viral diseases as well, it is more common after SARS-CoV infection. However, the mechanisms of SARS-CoV infection-related PF remain to be fully understood. Activation of transforming growth factor b (TGFb) pathway and increased degradation of angiotensin-converting enzyme2 (ACE2) or angiotensinogen system-mediated lung fibrosis may play major roles.

In the early phase of SARS infection, elevated serum levels of TGFb1 have been reported 10 . Activation of TGFb pathways leads to the production of fibrin, collagen, and secreted proteases (matrix metalloproteinases) 11 . Sime et al. had demonstrated the overexpression of active TGFb to result in severe interstitial and pleural fibrosis 12 . TGFb in the lungs is required to promote the differentiation of lung fibroblasts into myofibroblasts, which is necessary for pulmonary tissue repair after lung injury. SARS-CoV infection not only enhances the expression of TGFb but also facilitates its signaling activity through viral nucleocapsid (N) protein. Overexpression of N protein in lung epithelial and fibroblast cells potentiates TGFb-induced expression of platelet-activating factor I (PAI-I) and collagen I while attenuating Smad3/ Smad4-mediated apoptosis of human peripheral lung epithelial HPL1 cells. Thus, N protein modulates TGFb signaling and blocks apoptosis of SARS-CoV-infected host cells, besides promoting tissue fibrosis 13 .

Renin-angiotensin system is known to be activated after lung injury to promote tissue repair; when in excess, it may even lead to tissue fibrosis 14 . Angiotensin II (ANG II), converted from angiotensin I via the angiotensin-converting enzyme (ACE), is the major effector peptide in this function. ANG II has been found to be present at high levels in mice treated with bleomycin and in patients with PF, and is known to induce alveolar epithelial cell apoptosis 15 . AngII has profibrotic actions on growth factor expression, extracellular matrix synthesis, migration, and motility of lung fibroblasts mediated through both angiotensin type 1 receptor (AT1) and angiotensin type 2 receptor (AT2). ANGII can stimulate the production of TGFb in lung tissue mediated by AT1; TGFb itself can also regulate the level of ANGII. This "autocrine loop" involving ANGII and TGFb is believed to exist in lung tissues 16 . Application of ACE inhibitors, such as captopril, to inhibit ANGII production has been shown to attenuate experimental PF in animal models induced by bleomycin 17 . In 2000, a novel homolog of ACE, termed angiotensin-converting enzyme2 (ACE2) was identified 18 . ACE-2 could cleave Angiotensin II to a sevenamino acid peptide Ang1-7. Uhal et al. found Ang1-7 to act through its receptor Mas to inhibit bleomycin-induced fibrosis by inhibiting the activation of JNK, which is required for bleomycin and angiotensin II-induced apoptosis 15, 19 . Thus, ACE2 can act against lung fibrosis by the negative regulation of local AngII level. ACE2 is a membrane-anchored carboxypeptidase highly expressed in airway epithelial and type I and II alveolar epithelial cells; it was found to be the virus-cell entry receptor during the SARS-CoV outbreak 20 . The spike protein of SARS-CoV binds to ACE2 for entry and infects the target cells in humans 21 . Using a SARS infection model in ACE2 knockout mouse, Kuba et al. were able to show that ACE2 is indeed essential for SARS infection in vivo, and ACE2 expression in lungs is remarkably downregulated in wild-type mice infected with SARS-CoV 22,23 . The reduced expression of ACE2 may result in an increased ANGII level thereby leading to more severe lung fibrosis.

In patients with SARS, supportive care is the only proven beneficial treatment, including mechanical ventilation or in-line suction 24 . Antiviral drugs, such as ribavirin, are frequently used in patients, but their efficacy is yet to be proven. Significant toxicity is another issue in ribavirin-treated patients, with chances of approximately 76% hemolysis 25 . Even if steroids are used to prevent the cytokine storm, bone damage can be found in retrospective studies 26 . In this global emergency of the COVID-19 pandemic, physicians have tried every rational treatment, including the drugs against autoimmune and human immunodeficiency virus (like hydroxychloroquine) 27 ; however, the studies failed to show expected results. Tissues like bone marrow, adipose, placenta, and cord blood are rich in MSCs. Their characteristics may differ from the source 28 , but their common immunomodulating activities have been proven in both experimental research and clinical treatment, as in graft-versus-host disease (GvHD) 29, 30 . MSCs are hypoimmunogenic for alloreactive T-cells and have promoted hematological recovery in many preclinical trials 31 .

In animal studies, MSCs have shown potential in treating acute lung injury, ARDS, asthma, and fibrosis 32 ; their mechanisms of action might include the inhibition of inflammatory cytokines, such as TNFa 33, 34 . Thus, based on the passive defense method, virus-infected cells release interferons (IFNs) and stimulate genes like p21 to restrain cell growth. Stem cells may enhance this intrinsic viral resistance 35 . Khoury et al. had shown systemic MSC administration to potentially reduce lung injury after respiratory tract infections, such as influenza 36 . On the other hand, cell therapy offers an option for direct or indirect effects, like antiinflammation and improved regeneration through cellderived microvesicles or exosomes 37, 38 . Although many physicians are using the previous regimens with minor modifications for COVID-19 treatment, Chao et al. tested whether MSCs would have any therapeutic potential. In the study, seven patients received MSC infusion, and interestingly, all recovered from the symptoms, including high fever (38.5 + 0.5 C), weakness, shortness of breath, and low oxygen saturation 39 . However, the study was not well-documented in terms of the cell source and manufacturing details.

Despite the global pandemic threatening many lives, families, and economies worldwide, safety of any unproven treatment should be established carefully. Recently, many companies have been selling unlicensed cell-based treatments, such as stem cell products or kits for the extraction of exosomes 40 . This irresponsible behavior is not only harmful to the human body but also encroaches on other evidence-based and approved clinical studies. Although the therapeutic effects or benefits are still being evaluated, past experiences obtained from experiments and clinical trials have been contributing to patient and medical care. Based on most of the certified clinical trials, reports have suggested considerable effectiveness in the treatment of COVID-19 and PF. Thus, to improve the confidence of cell-based therapy, safety and rationale would be more important than effectiveness in this hopeless and distressing situation.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This review was funded by Buddhist Tzu Chi Bioinnovation Center, Tzu Chi Foundation (MF00A130SS04).

Hong-Meng Chuang https://orcid.org/0000-0003-1978-3618 Horng-Jyh Harn https://orcid.org/0000-0001-6777-3284 Ching-Ann Liu https://orcid.org/0000-0002-0392-7069

COVID-19 does not lead to a "typical" acute respiratory distress syndrome

Coronavirus disease 2019 (COVID-19): a clinical update

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?

A major outbreak of severe acute respiratory syndrome in Hong Kong

Pathology and pathogenesis of severe acute respiratory syndrome

Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS)

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome

The versatile role of matrix metalloproteinase for the diverse results of fibrosis treatment

Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung

Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factorbeta signaling

Angiotensin II and the fibroproliferative response to acute lung injury

Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway

Angiotensin-TGFbeta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages

Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor

A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Proapoptotic bid is required for pulmonary fibrosis

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Coronavirus spike proteins in viral entry and pathogenesis

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin-converting enzyme 2 protects from severe acute lung failure

SARS: epidemiology, clinical presentation, management, and infection control measures

Clinical features and shortterm outcomes of 144 patients with SARS in the greater Toronto area

Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood

Mesenchymal stem cells: mechanisms of immunomodulation and homing

Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients

Mesenchymal stem cell insights: prospects in hematological transplantation

Lung tissue damage associated with allergic asthma in BALB/c mice could be controlled with a single injection of mesenchymal stem cells from human bone marrow up to 14 d after transplantation

Mesenchymal stem cells for acute lung injury: preclinical evidence

Mesenchymal stem cell therapy of pulmonary fibrosis: improvement with target combination

Intrinsic immunity shapes viral resistance of stem cells

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases?

Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell

Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Preying on public fears and anxieties in a pandemic: businesses selling unproven and unlicensed "stem cell treatments" for COVID-19